Healthcare Services - Specialty Oncology / Value-Based Cancer Care
Strategic Profile
TOI is positioned for growth through 2028 with a target of ~20% annual revenue growth, driven by the migration toward comprehensive oncology care in a value-based landscape. 2026 is expected to represent TOI's first full year of Adjusted EBITDA profitability as a public company.
Cyborg Score Rationale
TOI anticipates 2026 revenue of $630-650 million, reflecting 28% growth and demonstrating strong market traction. The company is approaching profitability with 2026 expected to be its first full year of Adjusted EBITDA profitability as a public company. Recent board appointments and leadership promotions signal strengthening governance and operational execution.
Top Insights
2026 revenue guidance of $630-650M represents 28% YoY growth, with ~$150M from capitation revenue.
TOI deployed a near-touchless prior authorization workflow with >80% reduction in office-visit authorization submission time, freeing hundreds of staff hours weekly.
Recent board additions of Mark Stolper and Kim Tzoumakas bring healthcare industry expertise and operational leadership.
Chief Information Officer promotion of Rakesh Panda (25+ years IT/cybersecurity experience) signals focus on technology-enabled care delivery.
Named Competitors
Integrated Oncology Services — Specialty cancer treatment network